Evidence map›Paper›PMID 37245852›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2023

Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.

Cassandra E Meyer, Andrew W Smith, Aitana A Padilla-Requerey, Vista Farkhondeh, Noriko Itoh, Yuichiro Itoh, Josephine L Gao, Patrick D Herbig, Quynhanh Nguyen, Katelyn H Ngo and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Cassandra E MeyerDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Andrew W SmithDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Aitana A Padilla-RequereyDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Vista FarkhondehUCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Noriko ItohUCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Yuichiro ItohUCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Josephine L GaoDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Patrick D HerbigDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Quynhanh NguyenDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Katelyn H NgoDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Mandavi R OberoiDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Prabha SiddarthJane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California.
Rhonda R VoskuhlUCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California.
Allan MacKenzie-GrahamDepartment of Neurology, Ahmanson-Lovelace Brain Mapping Center, David Geffen School of Medicine at the University of California, Los Angeles, California; UCLA Multiple Sclerosis Program, Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, California. Electronic address: amg@ucla.edu.
University of California, Los Angeles · USUniversity of Southern California · US

Funding

Neurodegeneration Underlying Distinct Disabilities in Multiple Sclerosis Using a Cell-Specific, Region-Specific, and Sex-Specific ApproachR35NS132150 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RHONDA R VOSKUHL · 2023 to 2026
$3.6M
Neuroprotection in MS: A Cell-Specific and Region-Specific Transcriptomics ApproachR01NS109670 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2018 to 2022
$2.2M
AN INFORMATICS FACILITY FOR NEUROIMAGINGC06RR015431 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TOGA, ARTHUR W · 2000 to 2000
$2.0M
Bringing CLARITY to EAER01NS086981 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MACKENZIE-GRAHAM, ALLAN JAMES · 2015 to 2018
$1.3M
High Capacity Storage System for Computational BiologyS10OD011939 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WOODS, ROGER P · 2012 to 2012
$598k
The Mechanism of Gray Matter Atrophy in Experimental Autoimmune EncephalomyelitisR21NS121806 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MACKENZIE-GRAHAM, ALLAN JAMES · 2021 to 2021
$429k
Determining the neuroprotective role of estriol in experimental autoimmune encephalomyelitisF31NS105387 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MEYER, CASSANDRA EVE · 2018 to 2020
$111k
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR012169 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAZZIOTTA, JOHN C · 1996 to 1997
–
NCRR NIH HHS C06 RR012169NCRR NIH HHS C06 RR015431NIH HHS S10 OD011939NINDS NIH HHS F31 NS105387NINDS NIH HHS R01 NS086981NINDS NIH HHS R01 NS109670NINDS NIH HHS R21 NS121806NINDS NIH HHS R35 NS132150
6 · The paper itself

Abstract

In multiple sclerosis (MS), demyelination occurs in the cerebral cortex, and cerebral cortex atrophy correlates with clinical disabilities. Treatments are needed in MS to induce remyelination. Pregnancy is protective in MS. Estriol is made by the fetoplacental unit, and maternal serum estriol levels temporally align with fetal myelination. Here, we determined the effect of estriol treatment on the cerebral cortex in the preclinical model of MS, experimental autoimmune encephalomyelitis (EAE). Estriol treatment initiated after disease onset decreased cerebral cortex atrophy. Neuropathology of the cerebral cortex showed increased cholesterol synthesis proteins in oligodendrocytes, more newly formed remyelinating oligodendrocytes, and increased myelin in estriol-treated EAE mice. Estriol treatment also decreased the loss of cortical layer V pyramidal neurons and their apical dendrites and preserved synapses. Together, estriol treatment after EAE onset reduced atrophy and was neuroprotective in the cerebral cortex.

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisNeurodegenerative DiseasesAnimalsAtrophyCerebral CortexEstriolFemaleMiceMice, Inbred C57BLNeuroprotectionPregnancyEstriolestrogenexperimental autoimmune encephalomyelitismultiple sclerosisneurodegenerationneuroprotection

Identifiers

PMID37245852
PMCPMC11927460
OpenAlexW4378364334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.